<ul>
<li>华尔街看好的 3 只市值低于 20 美元的中盘股</li>
</ul>
<p>Ardelyx, Inc. (NASDAQ:ARDX - 免费报告) - HC Wainwright 的股票研究分析师在 7 月 3 日星期三发布的研究报告中上调了他们对 Ardelyx 2026 财年每股收益的预测。HC Wainwright 分析师 E. Arce 现预计，这家生物制药公司将在今年实现每股收益 0.68 美元，高于他们之前的预测 0.58 美元。Ardelyx 当前全年每股收益的共识预测为（0.36）美元。HC Wainwright 还预测 Ardelyx 2027 财年每股收益为 1.41 美元，2028 财年每股收益为 1.65 美元。</p>
<p>Ardelyx (NASDAQ:ARDX - 获取免费报告) 于 5 月 2 日星期四公布了其季度财报。这家生物制药公司报告该季度每股收益（EPS）为（0.11）美元，超过了（0.13）的共识预测 0.02 美元。该季度公司营收为 4,600 万美元，而分析师预测为 3,640 万美元。Ardelyx 净利润率为-41.36%，净资产收益率为-41.65%。公司季度营收同比增长 303.5%。去年同期，公司每股收益为（0.13）美元。</p>
<ul>
<li>2022 年初滑落后，Ardelyx 是否值得买入</li>
</ul>
<p>ARDX 成为其他几家研究机构关注的对象。Piper Sandler 将 Ardelyx 的评级从 “增持” 调降至 “中性”，并将公司的价格目标从 15.00 美元下调至 7.00 美元，日期为 7 月 2 日星期二。Leerink Partners 在 4 月 5 日星期五重申了对 Ardelyx 的 “表现优异” 评级。StockNews.com 在 6 月 28 日星期五的研究报告中将 Ardelyx 的评级从 “持有” 调降至 “卖出”。SVB Leerink 在 4 月 5 日星期五的研究报告中开始对 Ardelyx 进行覆盖。他们给出了一个 “表现优异” 的评级和 14.00 美元的价格目标。最后，Cantor Fitzgerald 在 6 月 20 日星期四的研究报告中重申了对 Ardelyx 的 “增持” 评级。一位分析师给予该股票卖出评级，一位持有评级，七位买入评级，一位强烈买入评级。根据 MarketBeat.com 的数据，该公司目前的共识评级为 “中度买入”，平均目标价为 11.31 美元。</p>
<p><strong>查看我们关于 ARDX 的最新报告</strong></p>
<h2>Ardelyx 股票表现</h2>
<p>周一，纳斯达克 ARDX 开盘价为 5.29 美元。Ardelyx 的 12 个月最低价为 3.16 美元，最高价为 10.13 美元。公司的速动比率为 4.36，流动比率为 4.53，资产负债比为 0.66。股票市值为 12.3 亿美元，市盈率为-18.89，贝塔系数为 0.83。公司的 50 天简单移动平均线为 6.93 美元，200 天简单移动平均线为 7.61 美元。</p>
<h2>对 Ardelyx 的对冲基金看法</h2>
<p>近期大型投资者已调整了他们对该公司的持股。HighMark Wealth Management LLC 在第一季度收购了 Ardelyx 的新股份，价值约 36,000 美元。Newbridge Financial Services Group Inc.在第一季度购入了 Ardelyx 的新头寸，价值约 64,000 美元。SJS Investment Consulting Inc.在第四季度购入了 Ardelyx 的新头寸，价值 62,000 美元。Jump Financial LLC 在第四季度收购了 Ardelyx 的新股份，价值 63,000 美元。最后，Paloma Partners Management Co 在第一季度购入了 Ardelyx 的新头寸，价值 86,000 美元。机构投资者拥有公司股份的 58.92%。</p>
<h2>内部人员的买卖行为</h2>
<p>在其他 Ardelyx 新闻中，内部人员 David P. Rosenbaum 于 6 月 3 日星期一以 7.00 美元的平均价格出售了公司股票的 17,872 股。交易完成后，该内部人员现直接持有公司股票 158,502 股，价值约 1,109,514 美元。该交易已在美国证券交易委员会的法律文件中披露，可通过此链接获得。另外，内部人员 Robert Blanks 于 6 月 21 日星期五以 5.96 美元的平均价格出售了公司股票 38,000 股。交易完成后，该内部人员现持有公司 324,331 股，价值 1,933,012.76 美元。该交易已在证券交易委员会的文件中披露，可通过此链接访问。此外，内部人员 David P. Rosenbaum 于 6 月 3 日星期一以 7.00 美元的平均价格出售了公司股票 17,872 股。股票总价值为 125,104.00 美元。交易完成后，该内部人员现持有公司股票 158,502 股，价值 1,109,514 美元。关于此次交易的披露可在此处找到。内部人员在过去 90 天内已出售了价值 4,117,225 美元的公司股票 534,119 股。公司股份的 5.50% 归公司内部人员所有。</p>
<h2>关于 Ardelyx（获取免费报告）</h2>
<p>Ardelyx, Inc.是一家生物制药公司，致力于在美国和国际市场上发现、开发和销售治疗胃肠和心脏肾脏疾病的药物。该公司的主要产品候选药物是 tenapanor，用于治疗具有便秘型肠易激综合征的患者。</p>
<h2>阅读更多</h2>
<ul>
<li>我们喜欢的五只比 Ardelyx 更好的股票</li>
<li>内部人员卖出解释：能否指导您的投资选择？</li>
<li>MarketBeat 周评 - 7/1 - 7/5</li>
<li>投资中降级意味着什么？</li>
<li>Constellation Brands 股票 2025 年第一季度：击败安海斯 - 布什？</li>
<li>复利利息如何计算？</li>
<li>高通股票在负面消息面前持续上涨</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVJEWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVJEWA"/></p>
<p><em>这则即时新闻警报是由叙事科技和来自 MarketBeat 的金融数据生成，旨在为读者提供最快速和最准确的报道。在发布之前，该故事已经经过 MarketBeat 编辑团队的审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com。</em></p>
<p>→ 奥巴马赢得总统辩论（来自 Porter &amp; Company）(广告)</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NjAw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NjAw"/></p>
<h2>现在是否值得投资$1,000 在 Ardelyx？</h2>
<p>在考虑 Ardelyx 之前，您可能想要听听这个。</p>
<p>MarketBeat 追踪华尔街评级最高且表现最佳的研究分析师以及他们每天向客户推荐的股票。MarketBeat 已经确定了五只顶级分析师悄悄告诉他们的客户现在购买的股票...而 Ardelyx 不在名单上。</p>
<p>虽然 Ardelyx 目前在分析师中有 “买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

ARDX

<p>HC Wainwright 已经提高了对 Ardelyx, Inc. (NASDAQ:ARDX) 2026 财年每股收益的预测。这家生物制药公司预计全年每股收益为$0.68，高于之前的预测$0.58。Ardelyx 目前的全年盈利共识预测为每股 ($0.36)。HC Wainwright 还发布了 2027 财年每股收益为$1.41 和 2028 财年每股收益为$1.65 的预测。该公司的股价周一开盘价为$5.29</p>

<ul>
<li>3 mid-caps under $20 that Wall Street loves</li>
</ul>
<div class="lb-trans"><ul>
<li>华尔街看好的 3 只市值低于 20 美元的中盘股</li>
</ul>
</div><p>Ardelyx, Inc. (NASDAQ:ARDX - Free Report) - Equities research analysts at HC Wainwright upped their FY2026 earnings per share estimates for Ardelyx in a research note issued on Wednesday, July 3rd. HC Wainwright analyst E. Arce now anticipates that the biopharmaceutical company will post earnings per share of $0.68 for the year, up from their previous forecast of $0.58. The consensus estimate for Ardelyx's current full-year earnings is ($0.36) per share. HC Wainwright also issued estimates for Ardelyx's FY2027 earnings at $1.41 EPS and FY2028 earnings at $1.65 EPS.</p>
<div class="lb-trans"><p>Ardelyx, Inc. (NASDAQ:ARDX - 免费报告) - HC Wainwright 的股票研究分析师在 7 月 3 日星期三发布的研究报告中上调了他们对 Ardelyx 2026 财年每股收益的预测。HC Wainwright 分析师 E. Arce 现预计，这家生物制药公司将在今年实现每股收益 0.68 美元，高于他们之前的预测 0.58 美元。Ardelyx 当前全年每股收益的共识预测为（0.36）美元。HC Wainwright 还预测 Ardelyx 2027 财年每股收益为 1.41 美元，2028 财年每股收益为 1.65 美元。</p>
</div><p>Ardelyx (NASDAQ:ARDX - Get Free Report) last posted its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.13) by $0.02. The company had revenue of $46.00 million for the quarter, compared to analyst estimates of $36.40 million. Ardelyx had a negative net margin of 41.36% and a negative return on equity of 41.65%. The business's quarterly revenue was up 303.5% on a year-over-year basis. During the same period last year, the business posted ($0.13) EPS.</p>
<ul>
<li>Is Ardelyx is A Buy After Slip in Early 2022</li>
</ul>
<div class="lb-trans"><p>Ardelyx (NASDAQ:ARDX - 获取免费报告) 于 5 月 2 日星期四公布了其季度财报。这家生物制药公司报告该季度每股收益（EPS）为（0.11）美元，超过了（0.13）的共识预测 0.02 美元。该季度公司营收为 4,600 万美元，而分析师预测为 3,640 万美元。Ardelyx 净利润率为-41.36%，净资产收益率为-41.65%。公司季度营收同比增长 303.5%。去年同期，公司每股收益为（0.13）美元。</p>
<ul>
<li>2022 年初滑落后，Ardelyx 是否值得买入</li>
</ul>
</div><p>ARDX has been the subject of several other research reports. Piper Sandler downgraded Ardelyx from an &#34;overweight&#34; rating to a &#34;neutral&#34; rating and cut their price objective for the company from $15.00 to $7.00 in a research report on Tuesday, July 2nd. Leerink Partnrs reaffirmed an &#34;outperform&#34; rating on shares of Ardelyx in a report on Friday, April 5th. StockNews.com cut Ardelyx from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research note on Friday, June 28th. SVB Leerink initiated coverage on Ardelyx in a research report on Friday, April 5th. They issued an &#34;outperform&#34; rating and a $14.00 price objective for the company. Finally, Cantor Fitzgerald reaffirmed an &#34;overweight&#34; rating on shares of Ardelyx in a research note on Thursday, June 20th. One analyst has rated the stock with a sell rating, one has issued a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $11.31.</p>
<div class="lb-trans"><p>ARDX 成为其他几家研究机构关注的对象。Piper Sandler 将 Ardelyx 的评级从 “增持” 调降至 “中性”，并将公司的价格目标从 15.00 美元下调至 7.00 美元，日期为 7 月 2 日星期二。Leerink Partners 在 4 月 5 日星期五重申了对 Ardelyx 的 “表现优异” 评级。StockNews.com 在 6 月 28 日星期五的研究报告中将 Ardelyx 的评级从 “持有” 调降至 “卖出”。SVB Leerink 在 4 月 5 日星期五的研究报告中开始对 Ardelyx 进行覆盖。他们给出了一个 “表现优异” 的评级和 14.00 美元的价格目标。最后，Cantor Fitzgerald 在 6 月 20 日星期四的研究报告中重申了对 Ardelyx 的 “增持” 评级。一位分析师给予该股票卖出评级，一位持有评级，七位买入评级，一位强烈买入评级。根据 MarketBeat.com 的数据，该公司目前的共识评级为 “中度买入”，平均目标价为 11.31 美元。</p>
</div><p><strong>Check Out Our Latest Report on ARDX</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 ARDX 的最新报告</strong></p>
</div><h2>Ardelyx Stock Performance</h2>
<div class="lb-trans"><h2>Ardelyx 股票表现</h2>
</div><p>NASDAQ ARDX opened at $5.29 on Monday. Ardelyx has a twelve month low of $3.16 and a twelve month high of $10.13. The company has a quick ratio of 4.36, a current ratio of 4.53 and a debt-to-equity ratio of 0.66. The stock has a market cap of $1.23 billion, a P/E ratio of -18.89 and a beta of 0.83. The company's 50-day simple moving average is $6.93 and its 200 day simple moving average is $7.61.</p>
<div class="lb-trans"><p>周一，纳斯达克 ARDX 开盘价为 5.29 美元。Ardelyx 的 12 个月最低价为 3.16 美元，最高价为 10.13 美元。公司的速动比率为 4.36，流动比率为 4.53，资产负债比为 0.66。股票市值为 12.3 亿美元，市盈率为-18.89，贝塔系数为 0.83。公司的 50 天简单移动平均线为 6.93 美元，200 天简单移动平均线为 7.61 美元。</p>
</div><h2>Hedge Funds Weigh In On Ardelyx</h2>
<div class="lb-trans"><h2>对 Ardelyx 的对冲基金看法</h2>
</div><p>Large investors have recently modified their holdings of the business. HighMark Wealth Management LLC acquired a new stake in Ardelyx during the first quarter worth approximately $36,000. Newbridge Financial Services Group Inc. bought a new position in Ardelyx in the first quarter worth approximately $64,000. SJS Investment Consulting Inc. bought a new position in shares of Ardelyx in the 4th quarter worth $62,000. Jump Financial LLC acquired a new stake in Ardelyx in the 4th quarter valued at $63,000. Finally, Paloma Partners Management Co acquired a new position in Ardelyx during the first quarter worth $86,000. Institutional investors own 58.92% of the company's stock.</p>
<div class="lb-trans"><p>近期大型投资者已调整了他们对该公司的持股。HighMark Wealth Management LLC 在第一季度收购了 Ardelyx 的新股份，价值约 36,000 美元。Newbridge Financial Services Group Inc.在第一季度购入了 Ardelyx 的新头寸，价值约 64,000 美元。SJS Investment Consulting Inc.在第四季度购入了 Ardelyx 的新头寸，价值 62,000 美元。Jump Financial LLC 在第四季度收购了 Ardelyx 的新股份，价值 63,000 美元。最后，Paloma Partners Management Co 在第一季度购入了 Ardelyx 的新头寸，价值 86,000 美元。机构投资者拥有公司股份的 58.92%。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部人员的买卖行为</h2>
</div><p>In other Ardelyx news, insider David P. Rosenbaum sold 17,872 shares of the firm's stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $7.00, for a total value of $125,104.00. Following the transaction, the insider now directly owns 158,502 shares of the company's stock, valued at approximately $1,109,514. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In other Ardelyx news, insider Robert Blanks sold 38,000 shares of the firm's stock in a transaction that occurred on Friday, June 21st. The shares were sold at an average price of $5.96, for a total value of $226,480.00. Following the sale, the insider now owns 324,331 shares in the company, valued at $1,933,012.76. The sale was disclosed in a document filed with the Securities &amp; Exchange Commission, which is accessible through this link. Also, insider David P. Rosenbaum sold 17,872 shares of the company's stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $7.00, for a total transaction of $125,104.00. Following the transaction, the insider now owns 158,502 shares of the company's stock, valued at $1,109,514. The disclosure for this sale can be found here. Insiders have sold 534,119 shares of company stock valued at $4,117,225 over the last 90 days. 5.50% of the stock is owned by corporate insiders.</p>
<div class="lb-trans"><p>在其他 Ardelyx 新闻中，内部人员 David P. Rosenbaum 于 6 月 3 日星期一以 7.00 美元的平均价格出售了公司股票的 17,872 股。交易完成后，该内部人员现直接持有公司股票 158,502 股，价值约 1,109,514 美元。该交易已在美国证券交易委员会的法律文件中披露，可通过此链接获得。另外，内部人员 Robert Blanks 于 6 月 21 日星期五以 5.96 美元的平均价格出售了公司股票 38,000 股。交易完成后，该内部人员现持有公司 324,331 股，价值 1,933,012.76 美元。该交易已在证券交易委员会的文件中披露，可通过此链接访问。此外，内部人员 David P. Rosenbaum 于 6 月 3 日星期一以 7.00 美元的平均价格出售了公司股票 17,872 股。股票总价值为 125,104.00 美元。交易完成后，该内部人员现持有公司股票 158,502 股，价值 1,109,514 美元。关于此次交易的披露可在此处找到。内部人员在过去 90 天内已出售了价值 4,117,225 美元的公司股票 534,119 股。公司股份的 5.50% 归公司内部人员所有。</p>
</div><h2>About Ardelyx (Get Free Report)</h2>
<div class="lb-trans"><h2>关于 Ardelyx（获取免费报告）</h2>
</div><p>Ardelyx, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation.</p>
<div class="lb-trans"><p>Ardelyx, Inc.是一家生物制药公司，致力于在美国和国际市场上发现、开发和销售治疗胃肠和心脏肾脏疾病的药物。该公司的主要产品候选药物是 tenapanor，用于治疗具有便秘型肠易激综合征的患者。</p>
</div><h2>Read More</h2>
<ul>
<li>Five stocks we like better than Ardelyx</li>
<li>Insider Selling Explained: Can it Inform Your Investing Choices?</li>
<li>MarketBeat Week in Review – 7/1 - 7/5</li>
<li>What Does Downgrade Mean in Investing?</li>
<li>Constellation Brands Stock Q1 2025: Crushing Anheuser-Busch?</li>
<li>How is Compound Interest Calculated?</li>
<li>Qualcomm Stock Continues to Rise in the Face of Negative News</li>
</ul>
<div class="lb-trans"><h2>阅读更多</h2>
<ul>
<li>我们喜欢的五只比 Ardelyx 更好的股票</li>
<li>内部人员卖出解释：能否指导您的投资选择？</li>
<li>MarketBeat 周评 - 7/1 - 7/5</li>
<li>投资中降级意味着什么？</li>
<li>Constellation Brands 股票 2025 年第一季度：击败安海斯 - 布什？</li>
<li>复利利息如何计算？</li>
<li>高通股票在负面消息面前持续上涨</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVJEWA" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NASDAQ&amp;Symbol=ARDX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>这则即时新闻警报是由叙事科技和来自 MarketBeat 的金融数据生成，旨在为读者提供最快速和最准确的报道。在发布之前，该故事已经经过 MarketBeat 编辑团队的审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><p>→ Obama wins Presidential debate (From Porter &amp; Company)(Ad)</p>
<div class="lb-trans"><p>→ 奥巴马赢得总统辩论（来自 Porter &amp; Company）(广告)</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NjAw" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=8600&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Ardelyx right now?</h2>
<div class="lb-trans"><h2>现在是否值得投资$1,000 在 Ardelyx？</h2>
</div><p>Before you consider Ardelyx, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Ardelyx 之前，您可能想要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ardelyx wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 追踪华尔街评级最高且表现最佳的研究分析师以及他们每天向客户推荐的股票。MarketBeat 已经确定了五只顶级分析师悄悄告诉他们的客户现在购买的股票...而 Ardelyx 不在名单上。</p>
</div><p>While Ardelyx currently has a &#34;Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Ardelyx 目前在分析师中有 “买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

HC Wainwright 上调了对 Ardelyx, Inc. (NASDAQ:ARDX) 的 2026 财年每股收益预期